Trials / Completed
CompletedNCT06603220
A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria
An Open Label Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Evommune, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This phase 2a trial will evaluate the safety and efficacy of EVO756 in subjects with chronic inducible urticaria, including symptomatic dermographism and cold urticaria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oral EVO756 | Oral EVO756, once daily |
Timeline
- Start date
- 2024-08-14
- Primary completion
- 2025-05-08
- Completion
- 2025-05-08
- First posted
- 2024-09-19
- Last updated
- 2025-06-18
Locations
18 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06603220. Inclusion in this directory is not an endorsement.